We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+16.05%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$11.4B
AUM Growth
-$622M
Cap. Flow
-$2.95B
Cap. Flow %
-25.85%
Top 10 Hldgs %
75.13%
Holding
138
New
10
Increased
24
Reduced
17
Closed
12

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$1.13B
2
ABBV icon
AbbVie
ABBV
+$938M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$82.3M
4
ATYR
aTyr Pharma
ATYR
+$51.8M
5
DYAX
DYAX CORPORATION
DYAX
+$50.5M

Top Sells

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$2.31B
2
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$1.14B
3
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$38M
4
VNDA icon
Vanda Pharmaceuticals
VNDA
+$14.5M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$13M

Sector Composition

Rank Sector Weight
1 Healthcare 77.51%
2 Technology 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGMO
26
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$35.8M 0.31%
3,230,932
+1,826,388
+130% +$23.5M
IMGN
27
DELISTED
Immunogen Inc
IMGN
$33.4M 0.29%
2,320,424
+1,320,928
+132% +$14.5M
TGTX icon
28
TG Therapeutics
TGTX
$8.31B
$33.2M 0.29%
2,003,991
-46,322
-2% -$733K
PGNX
29
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$32.5M 0.28%
4,350,808
– –
CPRX
30
DELISTED
Catalyst Pharmaceutical
CPRX
$30.3M 0.27%
7,335,692
-229,770
-3% -$916K
GILD icon
31
Gilead Sciences
GILD
$181B
$29.3M 0.26%
249,995
– –
KYTH
32
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$29.2M 0.26%
387,741
+33,476
+9% +$1.79M
NBIX icon
33
Neurocrine Biosciences
NBIX
$15.5B
$25.9M 0.23%
542,236
– –
ACGN
34
DELISTED
Aceragen Inc
ACGN
$25.9M 0.23%
51,308
+40
+0.1% +$18.4K
BLUE
35
DELISTED
bluebird bio
BLUE
$25.4M 0.22%
11,665
+349
+3% +$711K
DSCI
36
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$24.8M 0.22%
3,457,841
– –
ACOR
37
DELISTED
Acorda Therapeutics
ACOR
$24.6M 0.22%
6,158
– –
NVAX icon
38
Novavax
NVAX
$1.47B
$21.7M 0.19%
97,284
– –
FOMX
39
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$21M 0.18%
2,046,967
+225,000
+12% +$2.49M
XNCR icon
40
Xencor
XNCR
$2.07B
$19.2M 0.17%
872,072
– –
LKFT
41
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$19M 0.17%
+369,276
New +$19.6M
CLVS
42
DELISTED
Clovis Oncology, Inc.
CLVS
$17.8M 0.16%
202,630
– –
OMER icon
43
Omeros
OMER
$1.39B
$17.4M 0.15%
964,621
+327,175
+51% +$7.06M
ZGNX
44
DELISTED
Zogenix, Inc.
ZGNX
$16.8M 0.15%
1,253,571
+966,263
+336% +$11.8M
IOVA icon
45
Iovance Biotherapeutics
IOVA
$3.76B
$16.7M 0.15%
1,817,429
+492,429
+37% +$5.5M
PRQR icon
46
ProQR Therapeutics
PRQR
$330M
$16.5M 0.14%
988,299
+588,299
+147% +$11.1M
RPRX
47
DELISTED
Repros Therapeutics Inc.
RPRX
$14M 0.12%
1,955,944
-44,056
-2% -$343K
ACHN
48
DELISTED
Achillion Pharmaceuticals
ACHN
$13.5M 0.12%
1,523,739
+1,309,502
+611% +$12.4M
RARE icon
49
Ultragenyx Pharmaceutical
RARE
$2.55B
$12.7M 0.11%
123,894
-25,000
-17% -$1.94M
MTEM
50
DELISTED
Molecular Templates, Inc.
MTEM
$11.8M 0.1%
17,730
– –
1
2
3 4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q2 2015 Portfolio in Review

As of Q2 2015, Julian Baker held 138 positions worth $11.4B, down 5.2% from $12B the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Julian Baker withdrew a net $2.95B in Q2 2015, closing 12 positions and reducing 17 holdings. Its most notable exit was PHARMACYCLICS INC, an estimated $2.31B position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 46% a quarter earlier, followed by Technology.

Against the trend, Julian Baker opened a new position in Alexion Pharmaceuticals worth $1.18B.

  • Julian Baker's largest Q2 2015 buy was Alexion Pharmaceuticals: 6,542,599 shares worth $1.18B.
  • Julian Baker added most to Seagen Inc. Common Stock in Q2 2015, an estimated $82.3M increase.
  • Julian Baker's biggest Q2 2015 reduction was ANACOR PHARMACEUTICALS INC COM, cutting an estimated $38M.
  • Julian Baker fully exited PHARMACYCLICS INC in Q2 2015, selling an estimated $2.31B.
  • Julian Baker's ten largest holdings make up 75% of its $11.4B portfolio in Q2 2015.
  • Julian Baker opened 10 new positions and closed 12 in Q2 2015.
  • Julian Baker's portfolio value fell 5.2% quarter-over-quarter to $11.4B.

Based on Baker Bros. Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.